result lower
market challeng review
underscor impact vertic integr smaller scale
player support thesi cvs/express script
like benefit insourc dplo lost
volum announc review strateg busi altern
potenti upsid stock
focu remain infus estim repres total
profit infus revenu grew quarter modest deceler
growth still fastest grow highest margin
estim ebitda margin segment compani busi see exhibit
diplomat go forward compani abil monet
asset given defens market
infus busi worth given faster growth higher margin
profil infus busi think could take candid
entiti manag larg patient popul medic specialti spend
multipl bioscrip option merger announc back march
bull case valuat assum take multipl use transact
preced manag announc undergo review strateg
altern busi includ potenti sale entir
key data point call
chang custom rhetor around rebat manag cite
middl market client ask chang way rebat
structur prepar altern model focus
clinic valu proposit hope bring market long-term
pbm profit pressur gross profit/script declin y/i
sequenti see exhibit declin profit per script
partial driven million non-recurring pbm client rebat
payment incur due chang client drug mix due
 distribut unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
lost contract go forward believ pbm profit could
impact lower earn rebat lower volum could move
diplomat band pay fewer rebat reduc abil meet
sourc stabil manag see small improv
sourc agreement stabil sourc
agreement cardin
cut push ramp diplomat expect
 cost save vs prior expect
annual run rate exit year save push
due delay restructur facil consolid full
implement scriptm manag discuss look addit
opportun cost save next year would key help
increas pbm rfp volum provid upsid option
manag continu highlight higher rfp volum see
though sell season come close new contract
announc next catalyst watch
lower estim reduc revenu estim
million vs million previous
reduc adj ebitda estim
ebitda in-lin updat guidanc million million
ep estim move
exhibit specialti infus profit higher remaind busi
revenu total
includ oncolog hep immunolog multipl sclerosi hiv
compani data estim
exhibit quarterli chang script gross profit
gross profit
dplo ew pt base case dcf includ termin growth wacc
risk achiev pt includ delay biopharmaceut pipelin particularli ldd
product inabl target anticip synergi reimburs risk
dir fee exclus narrow network chang rebat polici
addit pbm contract loss specialti pressur off-set
